ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

ICP-490

A development code.

Its studies are mostly in Lymphoma, Non-Hodgkin · Multiple Myeloma, led by InnoCare Pharma.

Furthest: phase 2, since Jan 10, 20232 company-led studies, 2 open or runningNext primary completion: Jul 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
InnoCare Pharma22 open or runningphase 2since Jan 10, 2023Jan 10, 2023Jul 2028phase 2 · NCT06845241

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 10, 2023First study: phase 2 study in Relapsed and/or Refractory Multiple MyelomaFirst studyNCT05719701 · 80 planned · China
  2. Feb 20, 2025Phase 2 study in RecurrenceNCT06845241 · 68 planned · China

Ahead

  1. Jul 2028Primary completion: phase 2 study in RecurrenceNCT06845241

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06845241Recurrence · China2Not yet recruitingJul 202868
NCT05719701Relapsed and/or Refractory Multiple Myeloma · China2RecruitingJul 30, 202580

How it is read

Names in the registry

  • “ICP-490”, 2 entries

Codes read as this program: ICP490.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.